Comparison · NCT03232281-sae
Triptorelin Pamoate PR 3-month vs Triptorelin Acetate PR 1-month: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Triptorelin Pamoate PR 3-month vs Triptorelin Acetate PR 1-month: serious adverse events. Trial comparisons, record NCT03232281-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03232281-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0134 | 0.00369 | 0.0476 | wilson | |
| Risk in group 2 | 0.00667 | 0.00118 | 0.0368 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00676 | -0.0249 | 0.0414 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.01 | 0.185 | 22 | log | |
| Odds ratio, group 1 over group 2 | 2.03 | 0.182 | 22.6 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Triptorelin Pamoate PR 3-month than on Triptorelin Acetate PR 1-month | 148 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Triptorelin Pamoate PR 3-month | Subjects received 15 mg triptorelin pamoate per injection, administered as an IM injection once every 12 weeks (a total of 2 injections, at baseline and Week 12). | 2 | 149 | EG000 |
| Group 2 | Triptorelin Acetate PR 1-month | Subjects received 3.75 mg triptorelin acetate per injection, administered as an IM injection once every 4 weeks (a total of 6 injections, at baseline and Weeks 4, 8, 12, 16 and 20). | 1 | 150 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Treatment-emergent adverse events (TEAEs) were monitored from Day 1 up to Week 28 (approximately 7 months).
Source ClinicalTrials.gov
Trial
- Title
Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis
- NCT number
- NCT03232281
- Phases
- PHASE3
- Conditions
- Endometriosis
- Interventions
- Triptorelin Pamoate PR 3-month, Triptorelin Acetate PR 1-month
- Lead sponsor
- Ipsen
- Results first posted
- 2021-10-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03232281?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03232281-sae